Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 69
mi
from
San Francisco, CA
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 69
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1297
mi
from
Aurora, CO
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1297
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1303
mi
from
Northbrook, IL
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1303
mi
from
Northbrook, IL
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 025
mi
from
Kansas City, KA
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 025
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1334
mi
from
Lenexa, KA
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1334
mi
from
Lenexa, KA
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 39
mi
from
Golden Valley, MN
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 39
mi
from
Golden Valley, MN
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 39
mi
from
Golden Valley, MN
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 39
mi
from
Golden Valley, MN
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12965
mi
from
Chesterfield, MO
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12965
mi
from
Chesterfield, MO
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1355
mi
from
New York, NY
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1355
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1356
mi
from
Charlotte, NC
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1356
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Columbus, OH
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1318
mi
from
Uniontown, OH
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1318
mi
from
Uniontown, OH
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 11084
mi
from
Halifax,
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 11084
mi
from
Halifax,
Click here to add this to my saved trials
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10552
mi
from
Saint Louis, MO
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10552
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Tau Imaging in Young Onset Dementia
[18F]-T807 PET/CT Imaging of Tau Pathology in Young Onset Focal Dementia
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Tau Imaging in Young Onset Dementia
[18F]-T807 PET/CT Imaging of Tau Pathology in Young Onset Focal Dementia
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Comprehensive Communication Intervention for Minimally Verbal Children With Autism
Comprehensive Communication Intervention for Minimally Verbal Children With Autism
Status: Enrolling
Updated:  12/31/1969
Metro Nashville Schools
mi
from
Nashville, TN
Comprehensive Communication Intervention for Minimally Verbal Children With Autism
Comprehensive Communication Intervention for Minimally Verbal Children With Autism
Status: Enrolling
Updated: 12/31/1969
Metro Nashville Schools
mi
from
Nashville, TN
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12284
mi
from
Tuscaloosa, AL
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12284
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10358
mi
from
Anaheim, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10358
mi
from
Anaheim, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10358
mi
from
Anaheim, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10358
mi
from
Anaheim, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10738
mi
from
Glendale, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10738
mi
from
Glendale, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 177
mi
from
Imperial, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 177
mi
from
Imperial, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 004
mi
from
Irvine, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 004
mi
from
Irvine, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 004
mi
from
Irvine, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 004
mi
from
Irvine, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 176
mi
from
Loma Linda, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 176
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Los Angeles, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Los Angeles, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 174
mi
from
Norwalk, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 174
mi
from
Norwalk, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10665
mi
from
Oceanside, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10665
mi
from
Oceanside, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10140
mi
from
Orange, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10140
mi
from
Orange, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
San Diego, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 169
mi
from
San Rafael, CA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 169
mi
from
San Rafael, CA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 038
mi
from
Englewood, CO
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 038
mi
from
Englewood, CO
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12287
mi
from
Washington,
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12287
mi
from
Washington,
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 30
mi
from
Boca Raton, FL
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 30
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12299
mi
from
Gainesville, FL
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12299
mi
from
Gainesville, FL
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 150
mi
from
Lake City, FL
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 150
mi
from
Lake City, FL
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1345
mi
from
Miami, FL
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1345
mi
from
Miami, FL
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1345
mi
from
Miami, FL
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1345
mi
from
Miami, FL
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10269
mi
from
Orlando, FL
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10269
mi
from
Orlando, FL
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 020
mi
from
Port Charlotte, FL
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 020
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10765
mi
from
Augusta, GA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10765
mi
from
Augusta, GA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 01
mi
from
Decatur, GA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 01
mi
from
Decatur, GA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1367
mi
from
Chicago, IL
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1367
mi
from
Chicago, IL
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1367
mi
from
Chicago, IL
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1367
mi
from
Chicago, IL
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 025
mi
from
Kansas City, KA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 025
mi
from
Kansas City, KA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1370
mi
from
Baltimore, MD
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1370
mi
from
Baltimore, MD
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 101
mi
from
Glen Burnie, MD
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 101
mi
from
Glen Burnie, MD
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 024
mi
from
Boston, MA
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 024
mi
from
Boston, MA
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 118
mi
from
Creve Coeur, MO
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 118
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13534
mi
from
Kansas City, MO
Addressing Involuntary Movements in Tardive Dyskinesia
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13534
mi
from
Kansas City, MO
Click here to add this to my saved trials